Lots of ‘CARTS’, not enough ‘work horses’! There are now ~40 CAR-T protocols in #lupus incl many presentations at #ACR24 -most are uncontrolled -selection of pts is key. We need a pathway forward for reg approval & guidelines for studies! @RheumNow @ACRheum 18abst #OOO4 https://t.co/Mckwvn3Ffn

• https://x.com/Janetbirdope/status/1857807655235879253/photo/1

Small but useful open label RCT of MMF vs CYC vs TAC in SLE nephritis Surprisingly similar rates of remission at week 24... suggests TAC could be an option for induction? #ACR24 @RheumNow Abstr#0670 https://t.co/rO0ufturHW

• https://x.com/EBRheum/status/1857807337664426337/photo/1
• https://x.com/EBRheum/status/1857807337664426337/photo/1

Upadacitinib (UPA), a new oral treatment option for GCA? Dr. Peter Merkel discusses SELECT-GCA. UPA15 + 26-week GC taper >> PBO with a 52-week GC taper for GCA remission. #ACR24 #ACRBest @RheumNow ABST#0770 https://t.co/UbQLVA8X7r

• https://x.com/JihaRheum/status/1857796768035213421/photo/1

It's been a wild ride over the last 20 years of RA b/tsDMARDs, and fascinating to see how our prescribing habits have changed over that time. MarketScan data tell a story of fashion and fame. What will the next 20 years be like? #ACR24 ABST0509 @jeffsparks @RheumNow https://t.co/wCcWgkHrvc

• https://x.com/drdavidliew/status/1857797170591912008/photo/1

Major update in tx for GCA beyond Toci SELECT-GCA showed upadacitinib 15mg daily achieving higher rates of remission with SHORTER (26wk) steroid use compared to placebo (52wk) No significant adverse safety signal w JAKi including MACE/malignancy @RheumNow #ACR24 Abstract 0770 https://t.co/45D0Txed2N

• https://x.com/Dr_Brian_MD/status/1857798289459961856/photo/1
• https://x.com/Dr_Brian_MD/status/1857798289459961856/photo/1

GLP1ra is now part of GDMT, including pts without diabetes. The role of rheums in prescribing these remain to be seen. - Dr Weber #ACR24 @rheumnow @ACRheum https://t.co/U9XEhGBXBN

• https://x.com/KDAO2011/status/1857799828735951159/photo/1
• https://x.com/KDAO2011/status/1857799828735951159/photo/1

#0509 📊 RA DMARD Trends in US (2001-2021) 🧑‍🤝‍🧑 407,728 DMARD starts in 229,365 patients 📉 csDMARD use fell (79.7% → 54.7%) ‼️Methotrexate dropped 29% → 15% 📈 bDMARDs (20.3% →33.1%),tsDMARDs (0.1% → 12.2%) both ⬆️⬆️ 💊Biosimilar uptake low #ACR24 @RheumNow @jeffsparks https://t.co/JepaWj7azY

• https://x.com/CaoilfhionnMD/status/1857801047302930494/photo/1

The TAPIR Trial on GPA shows higher (15.5%) relapse in the 0 mg prednisone arm vs. 4.2% in the 5 mg arm (OR 4.22), but does not impact PROs. Key finding: benefit of 5 mg/day seen only in non-rituximab regimens (20% vs. 2.6%, OR 9.50). Abstr#0774 Plenary 1 @RheumNow #ACR24… https://t.co/5DjW5Zwh0J https://t.co/UnsVPzJfs6

• https://x.com/i/web/status/1857791986553540805
• https://x.com/synovialjoints/status/1857791986553540805/photo/1

SELECT-GCA: Upa in GCA Merkel Upa 15 mg v 7.5 v PBO w slower GC taper 70% new onset, 30% relapse. Few prev on IL6 Primary endpt: sustained remission at w52- UPA 15 mg beats PBO (p=0.0019) 34% relapse in UPA vs 60% PBO Less steroids, longer time to flare @RheumNow #ACR24 #ACRBest https://t.co/1OV2889Ny0

• https://x.com/ericdeinmd/status/1857794819352825977/photo/1
• https://x.com/ericdeinmd/status/1857794819352825977/photo/1
• https://x.com/ericdeinmd/status/1857794819352825977/photo/1

#ACR24 Year in Review: 💡GLP1i significantly decreased knee OA pain over time (or was it the wt loss itself?🤨) 💡CD19 CAR T-Cell therapy has potential to treat/cure many autoimmune diseases (are risks and $ worth the benefit?) 💡 High risk of CV events within 30 days of gout… https://t.co/XF63zr6lk4 https://t.co/oRNri66Il9

• https://x.com/i/web/status/1857779533933396132
• https://x.com/AdelaCastro222/status/1857779533933396132/photo/1
• https://x.com/AdelaCastro222/status/1857779533933396132/photo/1
• https://x.com/AdelaCastro222/status/1857779533933396132/photo/1